elcome to STAT’s Biotech Q1 Scorecard, our emoji-enabled means of tracking 11 make-or-break events expected over the next three months. When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate sunglassed smiley, rocket ship, or, if merited, smiling pile of excrement. Read on for brief explanations of what we’re watching for from each company.

(If you’re wondering why Axovant Sciences (AXON) and AveXis (AVXS) are missing, it’s because they got ahead of the rest of the pack. For Axovant’s compound misfortune of trial failure and embarrassing correction, let’s go with this emoji; for AveXis’ situation with the FDA, we’ll do this one.)

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.